LifeMap Sciences to Present Novel WGS Structural Variation Interpretation at PMWC 2019

ALAMEDA, Calif.--(BUSINESS WIRE)-- LifeMap Sciences, a subsidiary of AgeX Therapeutics, Inc., announced today that it will be presenting its novel whole genome sequencing (WGS) interpretation solutions at Precision Medicine World Conference 2019 in Silicon Valley, on January 22^nd, as part of the Clinical and Research Tools Showcase.

The presentation will discuss the challenges faced by clinics in interpreting large and complex data from WGS, and will describe how LifeMap’s NGS Analysis & Interpretation platform, TGex, is used to tackle these challenges. TGex leverages the GeneCards Knowledgebase and its sophisticated big data analysis tools for knowledge-driven interpretation.

LifeMap Sciences’ TGex is a leading provider of tertiary NGS analysis and interpretation solutions for rare pediatric disorders. It is today the clinical genetics solution of choice for top tier pediatric and maternal hospitals in China, Hong Kong and Italy amongst others, including Bambino Gesù, the largest pediatric research center in Italy, and top tier pediatric hospitals in China and Hong Kong. LifeMap also provides TGex to leading sequencing companies such as Novogene Tianjin Medical Laboratory in China.

The presentation will also include a live demonstration of WGS analysis and interpretation using TGex and the GeneCards Knowledgebase, on various cohorts of patients such as rare genetic disorders and cancer predisposition, including analysis of structural variations and regulatory elements.

LifeMap will also be exhibiting in Booth #506 at PMWC.

For inquiries, or for scheduling of private demonstrations of TGex and the GeneCards Suite’s NGS interpretation solutions, please contact Yaron Guan-Golan, CEO of LifeMap Sciences, at yg@lifemapsc.com.

About LifeMap Sciences

LifeMap Sciences is a life sciences technology company that offers integrated, streamlined solutions that empower life scientists worldwide to conduct cutting-edge basic, clinical and applied biomedical research. LifeMap’s products are used in more than 3,000 institutions including academia, research hospitals, patent offices, and leading biopharma and diagnostic companies. Operations worldwide are carried out from our offices in California, Massachusetts, New Jersey, Tel Aviv, and Hong Kong. LifeMap is a subsidiary of AgeX Therapeutics, Inc.

For more information, please visit http://www.lifemapsc.com/.

About AgeX Therapeutics

AgeX Therapeutics, Inc. is focused on developing and commercializing innovative therapeutics for human aging. Its PureStem® and UniverCyte™ manufacturing and immunotolerance technologies are designed to work together to generate highly defined, universal, allogeneic, off-the-shelf pluripotent stem cell-derived young cells of any type for application in a whole host of diseases with a high unmet medical need. AgeX has two preclinical cell therapy programs: AGEX-VASC1 (vascular progenitor cells) for tissue ischemia and AGEX-BAT1 (brown fat cells) for Type II diabetes. AgeX’s revolutionary longevity platform named induced Tissue Regeneration (iTR™) aims to unlock cellular immortality and regenerative capacity to reverse age-related changes within tissues. AGEX-iTR1547 is an iTR-based formulation in preclinical development. HyStem® is AgeX’s delivery technology to stably engraft PureStem cell therapies and slowly release iTR molecules in the body. AgeX is aggressively developing its core product pipeline for use in the clinic to extend human healthspan, and is seeking opportunities to form licensing and partnership agreements around its broad IP estate and proprietary technology platforms for non-core clinical applications.

For more information, please visit www.agexinc.com or connect with the company on Twitter, Facebook and YouTube.

Forward-Looking Statements

Certain statements contained in this release are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not historical fact including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates” should also be considered forward-looking statements. Forward-looking statements involve risks and uncertainties. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the business of AgeX Therapeutics, Inc. and its subsidiaries, particularly those mentioned in the cautionary statements found in more detail in the “Risk Factors” section of AgeX’s Information Statement filed as an exhibit to its Registration Statement on Form 10 with the Securities and Exchange Commissions (copies of which may be obtained at www.sec.gov). Subsequent events and developments may cause these forward-looking statements to change. AgeX specifically disclaims any obligation or intention to update or revise these forward-looking statements as a result of changed events or circumstances that occur after the date of this release, except as required by applicable law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190117005224/en/